- Home
- CMMB vs TXMD Comparison
CMMB vs TXMD Comparison
Compare CMMB & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- TXMD
- Stock Information
- Founded
- CMMB 2004
- TXMD 2008
- Country
- CMMB Israel
- TXMD United States
- Employees
- CMMB N/A
- TXMD N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- TXMD Health Care
- Exchange
- CMMB Nasdaq
- TXMD Nasdaq
- Market Cap
- CMMB 13.7M
- TXMD 12.3M
- IPO Year
- CMMB N/A
- TXMD N/A
- Fundamental
- Price
- CMMB $2.58
- TXMD $1.28
- Analyst Decision
- CMMB Strong Buy
- TXMD
- Analyst Count
- CMMB 2
- TXMD 0
- Target Price
- CMMB $26.50
- TXMD N/A
- AVG Volume (30 Days)
- CMMB 151.5K
- TXMD 517.8K
- Earning Date
- CMMB 11-12-2025
- TXMD 11-12-2025
- Dividend Yield
- CMMB N/A
- TXMD N/A
- EPS Growth
- CMMB N/A
- TXMD N/A
- EPS
- CMMB N/A
- TXMD N/A
- Revenue
- CMMB N/A
- TXMD $2,559,000.00
- Revenue This Year
- CMMB N/A
- TXMD $427.09
- Revenue Next Year
- CMMB N/A
- TXMD N/A
- P/E Ratio
- CMMB N/A
- TXMD N/A
- Revenue Growth
- CMMB N/A
- TXMD 156.93
- 52 Week Low
- CMMB $2.39
- TXMD $0.70
- 52 Week High
- CMMB $9.84
- TXMD $2.44
- Technical
- Relative Strength Index (RSI)
- CMMB 38.12
- TXMD 61.55
- Support Level
- CMMB $2.95
- TXMD $1.11
- Resistance Level
- CMMB $2.80
- TXMD $1.28
- Average True Range (ATR)
- CMMB 0.26
- TXMD 0.10
- MACD
- CMMB -0.09
- TXMD -0.00
- Stochastic Oscillator
- CMMB 2.30
- TXMD 68.97
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.